Document is current
Any future updates will be listed below
-
Authors
Ishitobi, Makoto https://orcid.org/0000-0002-0916-1244
Matsuda, Naoko
Tazo, Mizuho
Nakayama, Sayuka
Tokui, Ryu
Ogawa, Tomoko
Yoshida, Atsushi
Kojima, Yasuyuki
Kuwayama, Takashi
Nakayama, Takahiro
Yamauchi, Hideko
Nakamura, Seigo
Tsugawa, Koichiro
Hayashi, Naoki
-
Funding
Funding for this research was provided by:
Okasan-Kato Foundation
- License Information
-
More Information
Article History
Received: 22 June 2020
Accepted: 7 September 2020
First Online: 6 October 2020
Disclosure
: Makoto Ishitobi has received grants from the Okasan-Kato Foundation and from the Mie Prefectural Health Management Center during the performance of the study as well as personal fees from Chugai, AstraZeneca, Pfizer, Taiho, and Kyowa Kirin outside the submitted work. Atsushi Yoshida has received personal fees from Chugai Phama outside the submitted work. Yasuyuki Kojima has received personal fees from Chugai pharmaceutical, Eisai, Novartis pharma, Taiho pharma, Daiichi Sankyo, Pfizer, Eli Lilly, AstraZeneca, and Kyowa-Kirin outside the submitted work. Takahiro Nakayama has received honoraria from Chugai, AstraZeneca, Novartis, Eli Lilly, Pfizer, Ono, Taiho, and Takeda. Hideko Yamauchi has received personal fees from AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd, Allergan Japan K.K., Pfizer Japan, Inc., Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K.K. outside the submitted work. Seigo Nakamura has received personal fees from AstraZeneca K.K., Bayer Yakuhin, Ltd.; grants and personal fees from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., and Kyowa Kirin Co., Ltd.; grants from Novartis Pharma K.K.; grants and personal fees from Pfizer Japan, Inc.; personal fees from Sawai Pharmaceutical Co., Ltd. and Shionogi & Co., Ltd.; grants and personal fees from Taiho Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. outside the submitted work. Koichiro Tsugawa has received grants and personal fees from Astra Zeneka, Chugai Pharmaceutical Co., Ltd. and Eizai, grants; personal fees from Taiho Pharmaceutical Co, Ltd.; grants and personal fees from Takeda Pharmaceutical Co. Ltd and Nippon Kayaku Co., Ltd.; grants from MSD K.K.; personal fees from Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd. and Pfizer outside the submitted work. Naoki Hayashi has received personal fees from Chugai, Novartis, Astrazeneca, Kirin, Genomic Health, Inc., Allergan, Devixcor Japan, and Pfizer outside the submitted work. The remaining authors have no conflicts of interest.
